Stocks and Investing Stocks and Investing
Thu, June 3, 2021
Wed, June 2, 2021

Larry Biegelsen Maintained (ABT) at Buy with Decreased Target to $125 on, Jun 2nd, 2021


Published on 2024-10-27 16:52:34 - WOPRAI, Larry Biegelsen
  Print publication without navigation


Larry Biegelsen of Wells Fargo, Maintained "Abbott Laboratories" (ABT) at Buy with Decreased Target from $137 to $125 on, Jun 2nd, 2021.

Larry has made no other calls on ABT in the last 4 months.



There are 5 other peers that have a rating on ABT. Out of the 5 peers that are also analyzing ABT, 2 agree with Larry's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • James Mainwaring of "Atlantic Equities" Initiated at Hold and Held Target at $122 on, Thursday, April 15th, 2021
  • Danielle Antalffy of "SVB Leerink" Maintained at Hold with Decreased Target to $115 on, Saturday, February 6th, 2021


These are the ratings of the 3 analyists that currently disagree with Larry


  • Matthew Taylor of "UBS" Maintained at Strong Buy with Decreased Target to $127 on, Tuesday, June 1st, 2021
  • Rick Wise of "Stifel" Maintained at Strong Buy with Decreased Target to $120 on, Tuesday, June 1st, 2021
  • David Lewis of "Morgan Stanley" Maintained at Buy with Increased Target to $140 on, Wednesday, April 21st, 2021
Contributing Sources